Matthew Schuelke

469 total citations
10 papers, 290 citations indexed

About

Matthew Schuelke is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Matthew Schuelke has authored 10 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Immunology and 4 papers in Genetics. Recurrent topics in Matthew Schuelke's work include CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Matthew Schuelke is often cited by papers focused on CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers) and Immunotherapy and Immune Responses (4 papers). Matthew Schuelke collaborates with scholars based in United States, United Kingdom and Germany. Matthew Schuelke's co-authors include Richard G. Vile, Laura Evgin, Amanda L. Huff, Jill Thompson, Christopher B. Driscoll, Kevin G. Shim, José S. Pulido, Phonphimon Wongthida, Jason M. Tonne and Matt Coffey and has published in prestigious journals such as Nature Communications, Brain and Molecular Therapy.

In The Last Decade

Matthew Schuelke

10 papers receiving 287 citations

Peers

Countries citing papers authored by Matthew Schuelke

Since Specialization

Citations

This map shows the geographic impact of Matthew Schuelke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Schuelke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Schuelke more than expected).

Fields of papers citing papers by Matthew Schuelke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Schuelke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Schuelke. The network helps show where Matthew Schuelke may publish in the future.

Co-authorship network of co-authors of Matthew Schuelke

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Schuelke. A scholar is included among the top collaborators of Matthew Schuelke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Schuelke. Matthew Schuelke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors 2022 ·Neuro-Oncology Advances ·Matthew Schuelke, Justin H. Gundelach, Matt Coffey, Emma J. West, Karen J. Scott, Derek R. Johnson, Adel Samson, Alan Melcher, Richard G. Vile, Richard J. Bram	20
2	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy 2020 ·Nature Communications ·Christopher B. Driscoll, Matthew Schuelke, Timothy Kottke, Jill Thompson, Phonphimon Wongthida, Jason M. Tonne, Amanda L. Huff, Amber Miller, Kevin G. Shim, Amy M. Molan, Cynthia Wetmore, Peter J. Selby, Adel Samson, Kevin J. Harrington, Hardev Pandha, Alan Melcher, José S. Pulido, Reuben S. Harris, Laura Evgin, Richard G. Vile	49
3	Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses 2020 ·Molecular Therapy ·Amanda L. Huff, Laura Evgin, Jill Thompson, Tim Kottke, Christopher B. Driscoll, Jason M. Tonne, Phonphimon Wongthida, Matthew Schuelke, Kevin G. Shim, Georges Mer, Marina Ramı́rez-Alvarado, Richard G. Vile	5
4	Oncolytic virus-derived type I interferon restricts CAR T cell therapy 2020 ·Nature Communications ·Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason M. Tonne, Matthew Schuelke, Katayoun Ayasoufi, Christopher B. Driscoll, Kevin G. Shim, (unknown), Dileep D. Monie, Aaron J. Johnson, Matt Coffey, Sarah L. Young, Gary E. Archer, John H. Sampson, José S. Pulido, (unknown), Richard G. Vile	92
5	Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors 2020 ·Neuro-Oncology ·Phonphimon Wongthida, Matthew Schuelke, Christopher B. Driscoll, Timothy Kottke, Jill Thompson, Jason M. Tonne, Cathy Stone, Amanda L. Huff, Cynthia Wetmore, James A. Davies, Alan L. Parker, Laura Evgin, Richard G. Vile	12
6	Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators 2020 ·Brain ·Katayoun Ayasoufi, Christian K. Pfaller, Laura Evgin, Roman H. Khadka, (unknown), Emma N. Goddery, Cori E. Fain, (unknown), Benjamin Himes, Fang Jin, Jiaying Zheng, Matthew Schuelke, Michael J. Hansen, Wesley Tung, Ian F. Parney, Larry R. Pease, Richard G. Vile, Aaron J. Johnson	51
7	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment 2019 ·Cancer Immunology Research ·Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, (unknown), Reuben S. Harris, Matt Coffey, José S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Richard G. Vile	13
8	Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity 2019 ·Journal for ImmunoTherapy of Cancer ·Matthew Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, José S. Pulido, Laura Evgin, Richard G. Vile	10
9	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy 2018 ·Molecular Therapy — Oncolytics ·Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy M. Molan, José S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard G. Vile	19
10	Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy 2017 ·Molecular Therapy ·Kevin G. Shim, Shane Zaidi, Jill Thompson, Tim Kottke, Laura Evgin, Karishma Rajani, Matthew Schuelke, Christopher B. Driscoll, Amanda L. Huff, José S. Pulido, Richard G. Vile	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact